All enrolled patients who gained a minimum of 1 dose of zosuquidar or placebo in the course of induction have been monitored with the occurrence of adverse events (439 people, 219 on zosuquidar and 210 on placebo). The most typical adverse activities were relevant to the duration of prolonged and https://collinjtze96307.sharebyblog.com/27943287/lrrk2-in-7-no-further-a-mystery